Let’s immediately clear the field of easy illusions: no, we are not yet faced with the definitive cure. But when it comes to metastatic pancreatic cancer, one of the most aggressive, silent and difficult to treat neoplasms, even a single step forward can be worth a lifetime. And the one recorded in the last few hours is not a step like the others: it is a decisive swerve that promises to radically change the history of oncology medicine.
Pancreatic cancer remains, to date, a real emergency: in Italy alone it causes around 15 thousand deaths every year, thanks to extremely limited therapeutic options so far. Now, however, a new experimental molecule administered in tablets, Daraxonrasib, has literally shaken the international scientific community, earning its presentation in the plenary session at the famous congress of the American Society of Clinical Oncology.
Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer
Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived #ASCO26 pic.twitter.com/yS9E5kGHs1
— Mark Lewis, MD, FASCO (@marklewismd) May 31, 2026
The data from the global phase 3 study speak clearly: in patients with already metastatic and previously treated cancer, the new pill almost doubled survival compared to traditional chemotherapy. According to oncologists, this is the greatest success in the treatment of this neoplasm in decades.
The turning point numbers: survival doubled
The trial involved 500 patients around the world who had already failed the first cycles of treatment. Divided into two groups, half took the new oral drug, the other half the classic chemotherapy. The clinical results went beyond expectations. Average overall survival went from 6.7 months (with chemo) to 13.2 months with Daraxonrasib. One year after the start of therapy, 53.2% of patients treated with the new molecule are alive compared to just 17.3% of those who continued with chemotherapy. The time in which the tumor remained stationary, without progressing, doubled from 3.5 to over 7 months.
How the pill that “tricks” the tumor works
To understand the significance of this discovery we must come to terms with the biology of cancer. In more than 90% of cases, pancreatic adenocarcinoma is driven by a specific genetic mutation: the Kras gene. When this gene goes crazy, it turns into a perpetually on switch that tells cancer cells to multiply endlessly.
Daraxonrasib works like a smart “super switch”. It acts directly at the root: it enters the cells, binds to the diseased protein and turns it off. The real surprise of the study? The molecule proved effective not only in tumors with the mutated Kras gene, but also showed solid benefits in that rare percentage of patients who did not have the mutation.
Less toxicity and more quality of life
When fighting such an aggressive tumor, the quantity of life must go hand in hand with its quality. Second-line therapies used so far offered modest benefits despite substantial toxicity. Daraxonrasib has overturned this paradigm. Serious side effects were fewer than with chemo, but the most striking data concerns abandonment of treatment: only 1.2% of patients taking the pill had to stop treatment due to side effects, compared to 11.2% of those undergoing chemotherapy.
What happens now?
In the United States, given the extraordinary efficacy demonstrated, the treatment is already accessible to patients through a regulated compassionate use program, awaiting final commercial approval by the FDA.
The research, however, does not stop here. Daraxonrasib is already being tested for first-line treatment (i.e. for patients who have just been diagnosed with pancreatic cancer that is not yet metastatic) and to combat other types of cancer linked to mutations in the Ras gene. In the meantime, researchers are studying combinations of drugs to prevent the tumor from developing resistance to the pill over time.
“We are seeing unprecedented levels of survival and efficacy,” he enthuses from ASCO Rachna Shroffexpert in gastrointestinal tumorsUniversity of Arizona Cancer Center. “Targeting the Kras gene in pancreatic cancer is finally a reality.” The road is still long, but the therapeutic landscape has officially changed.